Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07151326 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

Study acronym: CAPIO
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment. 2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.
Trial Details
NCT Number NCT07151326
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital (TSGH), Mackay Memorial Hospital, Chang Gung Memorial Hospital, China Medical University Hospital, Taichung Veterans General Hospital, National Cheng-Kung University Hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC)
Related terms Carcinoma, Hepatocellular
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov